Health Care/Hospital

Harbour BioMed Reports the Online Publication of Phase I Results for HBM9378 (SKB378/WIN378), a TSLP-Targeting Antibody

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, March 22, 2026 /PRNewswire/ -- Harbour BioMed (HKEX: 02142, the "Company"), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics focusing on immunology and immune-oncology, today announ...

2026-03-23 11:14 4785

Everest Medicines Enters into Asset Purchase Agreement with Corxel Pharmaceuticals to Develop and Commercialize CARDAMYST™ (Etripamil) Nasal Spray in Greater China

SHANGHAI, March 23, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that it has entered into an Asset P...

2026-03-23 10:24 4688

SingWealth Holdings Strengthens Community Resilience Through Health, Wealth and Legacy Conversations at Lianhe Zaobao Event

SINGAPORE, March 23, 2026 /PRNewswire/ -- SingWealth Holdings ('SingWealth') recently stepped forward as the lead sponsor for Lianhe Zaobao'sMy Legacy and Living Well held on 21 March 2026, reinforcing the Group's commitment to helping Singaporeans navigate crit...

2026-03-23 10:00 3691

SORTIE Agency Honours Content Innovation with Kam Fan Bronze Award for Heroes in White

Redefining Brand Integration: A Strategic Narrative That Resonates with Audiences and Industry Alike HONG KONG, March 23, 2026 /PRNewswire/ -- SORTIE Agency has emerged as a standout at the 41st Kam Fan Awards, one of the advertising industry's most prestigious annual events, securing a Bronze a...

2026-03-23 09:00 2870

Innovent Announces First Participant Dosed of IBI128 (Tigulixostat, XOI) in Phase 3 Clinical Study

SAN FRANCISCO and SUZHOU, China, March 22, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune...

2026-03-23 08:00 3903

World Water Day: WuXi Biologics Advances Water Stewardship and Achieves Water Target

SHANGHAI, March 21, 2026 /PRNewswire/ -- On the occasion of World Water Day, WuXi Biologics reaffirms its commitment to sustainability through responsible operations and efficient, circular water‑use practices that reduce environmental impact. W...

2026-03-22 09:30 4033

Dizal Announces Positive Topline Phase 3 Results from WU-KONG28 Study: Evaluating Oral, Once-Daily ZEGFROVY® (Sunvozertinib) vs. Platinum-Containing Chemo Doublet in First-Line Non-Small Cell Lung Cancer (NSCLC) with EGFR Exon 20 Insertion Mutation (exon20ins)

* Treatment with ZEGFROVY® resulted in statistically significant and clinically meaningful improvement in progression free survival (PFS) over platinum-containing chemo doublet * WU-KONG 28 is the first and only phase 3 study to demonstrate meaningful benefits with an oral, once daily, chemo-...

2026-03-21 19:26 7197

Quality Protein No Longer a Luxury? Angel Yeast Shows How at FIC 2026

SHANGHAI, March 20, 2026 /PRNewswire/ -- Angel Yeast (SH600298) showcased its latest yeast protein R&D achievements and progress in global applications at FIC 2026 from March 17-19, 2026, reaffirming its commitment to making high-quality protein accessible to everyon...

2026-03-20 22:52 7905

Henlius Reports 2025 Results: Sustained Growth in Both Revenue and Profit, Advancing Innovation Validation and Global Operations

SHANGHAI, March 20, 2026 /PRNewswire/ -- Henlius (2696.HK) today announced its annual results for the year ended December 31, 2025. During the reporting period, the Company recorded revenue of RMB 6.6666 billion, representing a year-on-year increase of 16.5%, and net profit of RMB 0.8270 billion....

2026-03-20 21:21 10870

SiiPet Highlights Spring Health Priorities for Cats as Seasonal Initiative Expands Access to AI‑Driven Monitoring

LOS ANGELES, March 20, 2026 /PRNewswire/ -- SiiPet , a growing pet tech startup, announced itsSpring Sale initiative, running from March 15 to March 31, marking a renewed effort to make advanced feline health monitoring more widely accessible during a season when many ca...

2026-03-20 20:00 5127

Earendil Labs Announces $787 Million in Financing to Scale AI-Driven Biologics Discovery and Development

WILMINGTON, Del., March 20, 2026 /PRNewswire/ -- Earendil Labs, an AI-driven biotechnology company advancing next-generation biologics, today announced that it has raised$787 million in financing rounds. The investment included participation by a group of leading global investors, including Dimen...

2026-03-20 19:30 5042

HKSH Cancer Centre's Precision Targeting Technologies Leading the Evolution of "Hypofractionation"

Asia's First Study: 5 Sessions of Proton Therapy to Control Early-Stage Prostate Cancer HONG KONG, March 20, 2026 /PRNewswire/ -- HKSH Medical Group (HKSH) today announced the results of Asia's first clinical study on early-stage prostate cancer patients receiving five-session of proton therapy....

2026-03-20 19:10 5595

Manulife Named "Asia's Best Insurance Provider for Wealth Management" by Euromoney

HONG KONG, March 20, 2026 /PRNewswire/ -- Manulife today announced it has been named "Asia's Best Insurance Provider for Wealth Management" at the 2026 Euromoney Private Banking Awards. The award recognizes Manulife's excellence in delivering tailored and innovative wealth and legacy planning sol...

2026-03-20 18:00 8470

Antengene Announces 2025 Full-Year Results: First TCE Out-licensing Validates Platform Value and Marks Inflection Point Towards 2026 Profitability

SHANGHAI and HONG KONG, March 20, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) today announced its full-year results for the period ending December 31, 2025, and provided an update on recent business highlights and strategic progress. Dr. Jay Mei, Antengene's...

2026-03-20 17:14 8126

World Oral Health Day 2026: FDI urges governments to turn UN oral health commitments into action

Landmark UN political declaration recognizes oral health as essential to tackling noncommunicable diseases GENEVA, March 20, 2026 /PRNewswire/ -- On World Oral Health Day  (WOHD), FDI World Dental Federation (FDI) is urging governments to translate the oral h...

2026-03-20 16:30 4094

Ribo expands beyond the liver with RiboPepSTAR™ - enabling targeted siRNA delivery to multiple organs

SUZHOU, China and MÖLNDAL, Sweden, March 20, 2026 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd.  ("Ribo" or "the Company", Hong Kong Stock Exchange code: 6938) had been invited to give a speech at the RNA Leaders Europe Conference in Vienna, Austria on March 19th, one of the top oligonucleot...

2026-03-20 14:44 5504

Professor Chun-Hung Chu: "Protecting Oral Health Is Protecting Quality of Life"

World Oral Health Day 2026:"A Happy Mouth Is… A Happy Life" HONG KONG, March 20, 2026 /PRNewswire/ -- A healthy mouth is the foundation of overall well-being and plays an important role in enhancing quality of life. This year, World Oral Health Day is celebrated under the theme "A Happy Mouth Is...

2026-03-20 13:05 3729

MGI Tech and NUS Pharmacy and Pharmaceutical Sciences Announce Collaboration on DCS Lab to Accelerate Multi-Omics Innovation in Pharmaceutical Sciences

SINGAPORE, March 20, 2026 /PRNewswire/ -- MGI Tech Singapore Pte. Ltd. ("MGI"), a company dedicated to developing core tools and technologies that drive innovation in life sciences, and the Department of Pharmacy and Pharmaceutical Sciences in the National University of Singapore's Faculty of Sci...

2026-03-20 11:17 6010

Alphamab Oncology Announces the First Patient Dosed in a Phase III Clinical Study for Triple-Negative Breast Cancer of TROP2/HER3 Bispecific ADC JSKN016

SUZHOU, China, March 20, 2026 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) today announced that the first patient has been dosed in a phase III clinical study (JSKN016-301) evaluating JSKN016, a novel TROP2/HER3 bispecific antibody-drug conjugate (ADC) for the treatment of triple-negat...

2026-03-20 10:04 4179

GI Innovation Announces First Clinical Supply Agreement to Explore Combination Therapy for Prostate Cancer

SEOUL, South Korea, March 19, 2026 /PRNewswire/ -- GI Innovation announced on 19th that it has entered into a clinical supply agreement with Johnson & Johnson to evaluate a combination therapy in patients with metastatic castration-resistant prostate cancer (mCRPC) in a phase1b clinical trial. ...

2026-03-20 09:29 3329
1 ... 31323334353637 ... 859